Log in

Relevant bibliographies by topics / Hepatitis treatment / Journal articles

To see the other types of publications on this topic, follow the link: Hepatitis treatment.

Journal articles on the topic 'Hepatitis treatment'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Hepatitis treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Djuraev, Jamolbek A., Shokhimardon Kh Khodjanov, Azizkhon Z. Shaumarov, et al. "MODERN METHODS OF TREATMENT OF VIRAL HEPATITIS." International Journal of Medical Sciences And Clinical Research 03, no. 02 (2023): 69–75. http://dx.doi.org/10.37547/ijmscr/volume03issue02-14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Fazylov, V. Kh. "Etiological and pathogenetic aspects of diagnosis and treatment of viral hepatitides." Kazan medical journal 94, no. 6 (2013): 785–92. http://dx.doi.org/10.17816/kmj1791.

Full text

Abstract:

The commencement address highlights the results of the long-term scientific research of the department of infectious diseases of the Kazan State Medical University on the problems of viral hepatitides diagnosis, treatment and prevention. The era of research of the acute viral hepatitides was based primarily on the clinical and biochemical differential diagnosis, considering epidemiologic data and specific prevention (vaccination) of hepatitis A and B. The development of modern technologies opened up new opportunities for etiologic decoding and morphologic evaluation of the infectious process a

APA, Harvard, Vancouver, ISO, and other styles

3

Salam, Abdul, Bilqis Aslam Baloch, Naseer Khan, Ghulam Sarwar, and Masoom ,. "SEROPREVALENCE OF HBsAg (HBS) AND ANTI-HCV." Professional Medical Journal 21, no. 04 (2018): 766–70. http://dx.doi.org/10.29309/tpmj/2014.21.04.2424.

Full text

Abstract:

Background: Hepatitis is the inflammation of liver caused by infectious and noninfectiousagents. Hepatitis B and C are inflammations of liver caused by the viruses which are themajor public health problems worldwide and the incidence is even more in our country.Objective: Objective of the study was, 1). To estimate the prevalence of hepatitis B and hepatitisC viruses infected persons among the general population coming to BMC Hospital. 2). To pointout the more affected area of Baluchistan. 3). To produce awareness in the people. 4). To bringthis issue in Government notice. Method: The data was

APA, Harvard, Vancouver, ISO, and other styles

4

Bock, Kirsten, Andrea Atkinson, Chelsea Elwood, and Alnoor Ramji. "Case report of Hepatitis C treatment during pregnancy." Journal of Case Reports and Images in Obstetrics and Gynecology 14, no. 2 (2023): 39–42. http://dx.doi.org/10.5348/100162z08kb2023cr.

Full text

Abstract:

Introduction: Despite the increasing availability of Hepatitis C (HCV) anti-viral therapy for adults, there is minimal data regarding treatment safety and efficacy during pregnancy. Case Report: A 33-year-old primiparous female underwent successful HCV treatment with direct-acting antivirals (DAAs) beginning at 26 weeks gestational age. Conclusion: This case demonstrates the effective treatment of HCV during pregnancy. Formal trials are still required to assess the long-term safety and efficacy as treatment with DAAs for Hepatitis C is not yet established in pregnancy.

APA, Harvard, Vancouver, ISO, and other styles

5

Downey, Nancy H. "Hepatitis C Treatment." Gastroenterology Nursing 31, no. 2 (2008): 162. http://dx.doi.org/10.1097/01.sga.0000316567.85555.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mayhew, Maren S. "Hepatitis C Treatment." Journal for Nurse Practitioners 7, no. 10 (2011): 875–76. http://dx.doi.org/10.1016/j.nurpra.2011.09.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Brook, M. G. "Treatment of hepatitis." Journal of Hospital Infection 11 (February 1988): 175–81. http://dx.doi.org/10.1016/0195-6701(88)90184-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Blatt, Carine Raquel, Bernd Storb, Nikolai Mühlberger, Mareni Rocha Farias, and Uwe Siebert. "Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment." Brazilian Journal of Pharmaceutical Sciences 50, no. 2 (2014): 345–52. https://doi.org/10.1590/S1984-82502014000200014.

Full text

Abstract:

Brazilian Guidelines to HCV treatment (2007) recommended that the first choice treatment for patients with chronic hepatitis C (CHC) and genotype 2 or 3 is interferon alpha (IFN) plus ribavirin (RBV) for 24 weeks. The aim of this study is compare the cost and effectiveness to Hepatitis C treatment in patients with genotype 2 or 3 of peginterferon alpha (PEG) as the first choice of treatment within PEG for those that do not respond to IFN. The target population is CHC patients with genotype 2 or 3 in Brazil. The interventions are: PEG-SEC (first IFN plus RBV for 24 weeks, after, for non-respond

APA, Harvard, Vancouver, ISO, and other styles

9

Ukashah, Muhamma. "Different Tools Used for Treatment of Chronic Hepatitis B." Open Access Journal of Endocrinology 6, no. 1 (2022): 1–5. http://dx.doi.org/10.23880/oaje-16000176.

Full text

Abstract:

Currently different vaccines are available for cure and medicines are also available since 1988 but still 250 million people are infected with hepatitis B virus. The viruses of hepatitis B and hepatitis C causes liver cancer and also tuberculosis and malaria. The well developed and under developing countries both are very poor in care that can reduce the risk of hepatitis B. If we talk about United States only one third of those people who are infected with this virus are aware of their infection. The main reason for this un awareness is that the asymptomatic nature of hepatitis B virus as the

APA, Harvard, Vancouver, ISO, and other styles

10

Nouman, Muhammad Khuram, Bushra Zaidi, Ghulam Mohiuddin, Faryal Asif, and Muhammad Khan Malik. "HEPATITIS C." Professional Medical Journal 25, no. 03 (2018): 387–91. http://dx.doi.org/10.29309/tpmj/2018.25.03.381.

Full text

Abstract:

Background: Hepatitis C virus (HCV) is the most communal source of non-A,non-B viral hepatitis in the world. The disease is illusory, and the majority of patients do notacquire jaundice at its onset. Treatment of hepatitis C with interferon attained a sustainedvirological response (SVR) in almost 50% of the patients with HCV infection. Viral genotype isimportant to determine the response. The present study aims to provide the incidence of relapseof HCV in patients taking interferon therapy and to identify the predictors for relapse. StudyDesign: Retrospective observational study. Setting: Depa

APA, Harvard, Vancouver, ISO, and other styles

11

Garty, Ben-Zion, Rivka Kauli, Josef Ben-Ari, Ernest Lubin, Menachem Nitzan, and Zvi Laron. "Hepatitis Associated with Propylthiouracil Treatment." Drug Intelligence & Clinical Pharmacy 19, no. 10 (1985): 740–42. http://dx.doi.org/10.1177/106002808501901009.

Full text

Abstract:

A 12-year-old girl with hyperthyroidism who had started treatment with propylthiouracil (PTU) 100 mg tid developed hepatitis. The drug was stopped, and the clinical and laboratory findings of hepatitis disappeared within a week. She was not receiving other drugs that could cause hepatic damage, and investigations for various viral agents were negative. This is the ninth report of PTU-induced hepatitis. The clinical picture is similar to that of viral hepatitis. Recovery usually occurs after withdrawal of the drug, but there have been two fatal cases of PTU-induced hepatitis.

APA, Harvard, Vancouver, ISO, and other styles

12

Malhotra, Parveen, Vani Malhotra, Yogesh Sanwariya, Ajay Chugh, Isha Pahuja, and Akshay Akshay. "Acute HBV Related ALF- Successful Outcome with Oral Antiviral Treatment." Clinical Research and Clinical Trials 5, no. 1 (2022): 01–03. http://dx.doi.org/10.31579/2693-4779/069.

Full text

Abstract:

Case report: We present a young female of fourteen years who was admitted to the hospital with short duration of Icterus, malaise, vomiting and diagnosed to be having acute hepatitis B. She went into acute liver failure as evidenced by development of hepatic encephalopathy and coagulopathy. She was managed on lines of hepatic encephalopathy along with oral antiviral treatment. She recovered successfully and was discharged after two weeks in heamodynamically stable condition. After a gap of six months, she became Hepatitis B surface (HbsAg) & hepatitis B e-antigen (HbeAg) negative and Hepat

APA, Harvard, Vancouver, ISO, and other styles

13

Treloar, Carla, and Martin Holt. "Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings." Australian Health Review 32, no. 3 (2008): 570. http://dx.doi.org/10.1071/ah080570.

Full text

Abstract:

This study explores the perception of and readiness for hepatitis C treatment within a sample of 77 clients already participating in drug treatment, with a view to identifying likely barriers and incentives to hepatitis C treatment within a drug treatment population. Participants with hepatitis C did not demonstrate a consistent, indepth knowledge of the infection, lacked confidence in symptom recognition, and had little awareness of treatment options. Those without obvious symptoms or liver deterioration did not have a pressing interest in treatment, and many had heard concerning stories abou

APA, Harvard, Vancouver, ISO, and other styles

14

VALLABHANENI, S., G. E. MACALINO, S. E. REINERT, B. SCHWARTZAPFEL, F. A. WOLF, and J. D. RICH. "Prisoners favour hepatitis C testing and treatment." Epidemiology and Infection 134, no. 2 (2005): 243–48. http://dx.doi.org/10.1017/s0950268805004991.

Full text

Abstract:

More people with hepatitis C virus pass through incarcerated settings each year than any other venue. The goal of this study was to assess inmates' attitudes towards hepatitis C testing and treatment while incarcerated. We interviewed 153 male and female inmates at the Rhode Island Department of Corrections (RIDOC). Ninety-one per cent of inmates said they would agree to be tested for hepatitis C and 95% said that they would be willing to be treated for hepatitis C while incarcerated. Thirty-three per cent perceived themselves to be at risk for hepatitis C. Inmates were very interested in hepa

APA, Harvard, Vancouver, ISO, and other styles

15

Loomba, Rohit, and T. Jake Liang. "Treatment of Chronic Hepatitis B." Antiviral Therapy 12, no. 3_suppl (2007): 33–41. http://dx.doi.org/10.1177/135965350701203s05.

Full text

Abstract:

Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease and hepatocellular carcinoma worldwide. Approximately 350 million individuals are infected with HBV and >500,000 deaths per year can be attributed to HBV. Although universal vaccination has reduced HBV incidence in many countries, it still remains a major public health problem, especially in parts of Asia and Africa. Improved understanding of HBV virology and virus-host interactions has revolutionized chronic hepatitis B therapy in the past two decades. Development of oral nucleoside/nucleotide analogues heralds

APA, Harvard, Vancouver, ISO, and other styles

16

Alatas, Fatima Safira, Gryselda Hanafi, Lestari Kanti Wilujeng, and Nielda Kezia Sumbung. "Autoimmune Hepatitis." Archives of Pediatric Gastroenterology, Hepatology, and Nutrition 1, no. 1 (2022): 17–27. http://dx.doi.org/10.58427/apghn.1.1.2022.17-27.

Full text

Abstract:

Autoimmune hepatitis (AIH) is a condition caused by self-perpetuating immune response towards hepatocytes in liver. In children, AIH may progressed more rapidly compared to adults. Thus, early diagnosis and prompt treatment are the key for successful management of AIH. Five main characteristics of AIH include female predominance, increased IgG or hypergammaglobulinemia, circulatory autoantibody seropositivity, and hepatitis interface from the histological finding. Liver biopsy is needed to evaluate the degree of damage and to confirm the diagnosis. The standard regiment for AIH include prednis

APA, Harvard, Vancouver, ISO, and other styles

17

Krzeczkowska, Anna, Paul Flowers, Zoe Chouliara, Peter Hayes, and Adele Dickson. "‘It’s been a long haul, a big haul, but we’ve made it’: hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis." Health Psychology Open 5, no. 2 (2018): 205510291879267. http://dx.doi.org/10.1177/2055102918792673.

Full text

Abstract:

The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-transplant patients with recurrent hepatitis C virus. Three themes were identified using interpretative phenomenological analysis. Participants reported an ongoing sense of ontological uncertainty characterized by lack of control over their condition and treatment. Furthermore, an apposition of scepticism and hope accompanying each stage of hepatitis C virus treatment was

APA, Harvard, Vancouver, ISO, and other styles

18

Krick, Stacie E., Kimberly A. Gwinn, and Douglas R. Morgan. "Pathophysiology and Treatment of Hepatitis C Infection." Journal of Pharmacy Practice 12, no. 5 (1999): 391–400. http://dx.doi.org/10.1177/089719009901200505.

Full text

Abstract:

The pathophysiology and treatment of hepatitis C infection, formerly known as non-A, non-B hepatitis, are discussed. The worldwide prevalence is approximately 1%. The majority of patients infected with hepatitis C virus will develop chronic infection, leading to cirrhosis in a significant percentage. Transmission of hepatitis C is primarily through parenteral routes. Those who use intravenous drugs or received blood transfusions prior to 1992 comprise the major risk groups for the infection. The progression of chronic hepatitis C infection is insidious with possible progression to an inflammat

APA, Harvard, Vancouver, ISO, and other styles

19

P, Mathew. "Autoimmune Hepatitis-Profile and Response to Treatment in Indian Patients." Gastroenterology & Hepatology International Journal 4, no. 2 (2019): 1–6. http://dx.doi.org/10.23880/ghij-16000159.

Full text

Abstract:

Introduction: Autoimmune hepatitis (AIH) can have varied manifestations, commonest presentation being as chronic liver disease. The data on the disease profile in India is scanty compared to the West. Aim: To study the clinical, biochemical, histological profile and response to treatment in patients with Auto-immune Hepatitis in Indian population. Methods: This is a Retrospective analysis of the twenty one (12 M = 57.1%; 9 F = 42.9%) patients diagnosed with AIH according to simplified criteria for diagnosis of AIH, in the last three years (2017-2019) in the department of medical gastroenterolo

APA, Harvard, Vancouver, ISO, and other styles

20

Ali, Hasan, Taqi Rizvi, Mumtaz Niazi, Mark Galan, and Nikolaos Pyrsopoulos. "Autoimmune Hepatitis Induced after Treatment of Syphilitic Hepatitis." Journal of Clinical and Translational Hepatology 000, no. 000 (2021): 000. http://dx.doi.org/10.14218/jcth.2020.00178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Lambiase, Louis, and Gary L. Davis. "TREATMENT OF CHRONIC HEPATITIS." Gastroenterology Clinics of North America 21, no. 3 (1992): 659–77. http://dx.doi.org/10.1016/s0889-8553(21)00054-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Komatsu, Haruki, Ayano Inui, and Tomoo Fujisawa. "Pediatric hepatitis B treatment." Journal of Thoracic Disease 5, no. 3 (2017): 37. http://dx.doi.org/10.21037/atm.2016.11.52.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Heathcote, J., and J. Main. "Treatment of hepatitis C." Journal of Viral Hepatitis 12, no. 3 (2005): 223–35. http://dx.doi.org/10.1111/j.1365-2893.2005.00600.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Niro, G. A., F. Rosina, and M. Rizzetto. "Treatment of hepatitis D." Journal of Viral Hepatitis 12, no. 1 (2005): 2–9. http://dx.doi.org/10.1111/j.1365-2893.2005.00601.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Shirokova, Irina, and Nadezhda Kalinina. "Hepatitis C treatment breakthroughs." Remedium Journal about the Russian market of medicines and medical equipment, no. 7-8 (2020): 19–22. http://dx.doi.org/10.21518/1561-5936-2020-7-8-19-22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sherlock, Dame Sheila. "Treatment of chronic hepatitis." Current Opinion in Gastroenterology 10, no. 3 (1994): 243–48. http://dx.doi.org/10.1097/00001574-199405000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Gerin, John L. "Treatment of viral hepatitis." Current Opinion in Infectious Diseases 5, no. 6 (1992): 806–10. http://dx.doi.org/10.1097/00001432-199212000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Morgan, Timothy. "Treatment of Alcoholic Hepatitis." Seminars in Liver Disease 9, no. 04 (1993): 384–94. http://dx.doi.org/10.1055/s-2007-1007367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Yuen, Man-Fung, and Ching-Lung Lai. "Treatment for Hepatitis B." Journal of Clinical Gastroenterology 38 (November 2004): S134—S135. http://dx.doi.org/10.1097/00004836-200411003-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Johnson, P. J. "Treatment of autoimmune hepatitis." Gut 41, no. 1 (1997): 3–4. http://dx.doi.org/10.1136/gut.41.1.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Carrasco, Daniel A., Catherine Newman, and Stephen K. Tyring. "Treatment of viral hepatitis." Dermatologic Therapy 13, no. 3 (2000): 318–25. http://dx.doi.org/10.1046/j.1529-8019.2000.00033.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Lerias de Almeida, Paulo Roberto. "Acute hepatitis C treatment." Annals of Hepatology 9 (2010): S107—S111. http://dx.doi.org/10.1016/s1665-2681(19)31734-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Antonio Olivera Martínez, Marco. "Treatment of Acute Hepatitis." Annals of Hepatology 5 (2006): S29—S31. http://dx.doi.org/10.1016/s1665-2681(19)31966-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Strassburg, Christian, and Michael Manns. "Treatment of Autoimmune Hepatitis." Seminars in Liver Disease 29, no. 03 (2009): 273–85. http://dx.doi.org/10.1055/s-0029-1233534.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Hunt, Summer. "New Hepatitis C Treatment." Nursing for Women's Health 21, no. 5 (2017): 335. http://dx.doi.org/10.1016/s1751-4851(17)30255-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Fulton, Scott, and Arthur J. McCullough. "TREATMENT OF ALCOHOLIC HEPATITIS." Clinics in Liver Disease 2, no. 4 (1998): 799–819. http://dx.doi.org/10.1016/s1089-3261(05)70043-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Raj, Vivek. "Treatment of hepatitis B." Clinical Cornerstone 3, no. 6 (2001): 24–36. http://dx.doi.org/10.1016/s1098-3597(01)90076-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Satoor, Sumalatha, and Jean-Pierre Raufman. "Treatment of hepatitis C." Clinical Cornerstone 3, no. 6 (2001): 37–46. http://dx.doi.org/10.1016/s1098-3597(01)90077-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

McConnell, John. "Hepatitis treatment moves on." Lancet 352, no. 9132 (1998): 964. http://dx.doi.org/10.1016/s0140-6736(05)61520-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wai, Chun Tao, and Anna S. F. Lok. "Treatment of hepatitis B." Journal of Gastroenterology 37, no. 10 (2002): 771–78. http://dx.doi.org/10.1007/s005350200129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Wu, Li-Wei, and Jia-Horng Kao. "Hepatitis during antituberculosis treatment." Journal of the Formosan Medical Association 110, no. 12 (2011): 801. http://dx.doi.org/10.1016/j.jfma.2011.11.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Pearlman, Brian L. "Hepatitis C treatment update." American Journal of Medicine 117, no. 5 (2004): 344–52. http://dx.doi.org/10.1016/j.amjmed.2004.03.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kim, Andrew I., and Sammy Saab. "Treatment of hepatitis C." American Journal of Medicine 118, no. 8 (2005): 808–15. http://dx.doi.org/10.1016/j.amjmed.2005.01.073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

O'Shea, Robert S., and Arthur J. McCullough. "Treatment of Alcoholic Hepatitis." Clinics in Liver Disease 9, no. 1 (2005): 103–34. http://dx.doi.org/10.1016/j.cld.2004.11.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Maher, Jacquelyn J. "Treatment of alcoholic hepatitis." Journal of Gastroenterology and Hepatology 17, no. 4 (2002): 448–55. http://dx.doi.org/10.1046/j.1440-1746.2002.02722.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Czaja, Albert J. "Treatment of Autoimmune Hepatitis." Seminars in Liver Disease 22, no. 4 (2002): 365–78. http://dx.doi.org/10.1055/s-2002-35706.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gunsar, Fulya. "Treatment of delta hepatitis." Expert Review of Anti-infective Therapy 11, no. 5 (2013): 489–98. http://dx.doi.org/10.1586/eri.13.35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Cooke, G. S., J. Main, and M. R. Thursz. "Treatment for hepatitis B." BMJ 340, jan05 2 (2010): b5429. http://dx.doi.org/10.1136/bmj.b5429.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Rodriguez-Luna, Hector, Erin Tharalson, Elizabeth Evanich, David A. Johnson, and Francisco C. Ramirez. "Treatment of Hepatitis C." American Journal of Gastroenterology 100 (September 2005): S133—S134. http://dx.doi.org/10.14309/00000434-200509001-00335.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Tran, Tram T., Fred Poordad, and Paul Martin. "Treatment of hepatitis C." Current Hepatitis Reports 2, no. 1 (2003): 3–8. http://dx.doi.org/10.1007/s11901-003-0008-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!